Alexion Pharma (ALXN) Tops Q4 EPS by 40c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Alexion Reports Fourth Quarter and Full Year 2020 Results
February 4, 2021 8:00 AM EST4Q20 total revenues of $1,591.8 million, a 15% increase over 4Q19 4Q20 GAAP diluted EPS of $2.42; non-GAAP diluted EPS of $2.96 Announced agreement to be acquired by AstraZeneca; transaction expected to close in Q3 2021 Received EU approval for ULTOMIRIS® (ravulizumab) 100 mg/mL higher concentration formulation in paroxysmal nocturnal hemoglobinuria (PNH) & atypical hemolytic uremic syndrome (aHUS) Continued advancement of pipeline, including initiation of three Phase 3 development programs and two novel IND filings in Q4 2020
BOSTON--(BUSINESS... More
